OSE Immunotherapeutics SA

LSE:0RAD Stock Report

Market Cap: €215.8m

OSE Immunotherapeutics Past Earnings Performance

Past criteria checks 4/6

OSE Immunotherapeutics has been growing earnings at an average annual rate of 7.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 12.9% per year. OSE Immunotherapeutics's return on equity is 56.5%, and it has net margins of 55.2%.

Key information

7.7%

Earnings growth rate

8.6%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate12.9%
Return on equity56.5%
Net Margin55.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How OSE Immunotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0RAD Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 248346821
31 Mar 244312819
31 Dec 232-23817
30 Sep 233-25920
30 Jun 234-281022
31 Mar 2311-231024
31 Dec 2218-181027
30 Sep 2226-131029
30 Jun 2233-71130
31 Mar 2230-121230
31 Dec 2126-171230
30 Sep 2120-211129
30 Jun 2114-25928
31 Mar 2112-21825
31 Dec 2010-17722
30 Sep 2013-12722
30 Jun 2016-8722
31 Mar 2021-6622
31 Dec 1926-5622
30 Sep 1923-4519
30 Jun 1920-3516
31 Mar 19221516
31 Dec 18245415
30 Sep 18245415
30 Jun 18245515
31 Mar 1816-3515
31 Dec 177-11515
30 Sep 175-10513
30 Jun 173-10411
31 Mar 172548
31 Dec 1602135
30 Sep 1602134
30 Jun 1602233
31 Mar 160833
31 Dec 150-632
30 Sep 150-532
30 Jun 150-522
31 Mar 150-422
31 Dec 140-312
30 Sep 140-211
30 Jun 140-100
31 Mar 140-100

Quality Earnings: 0RAD has high quality earnings.

Growing Profit Margin: 0RAD became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0RAD has become profitable over the past 5 years, growing earnings by 7.7% per year.

Accelerating Growth: 0RAD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 0RAD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: 0RAD's Return on Equity (56.5%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies